Low-dose naltrexone (LDN) could treat patients with Crohn's Disease, Alzheimer’s, ovarian and pancreatic cancers, AIDS, autism and MS, to name just a few.
Naltrexone is a pharmacologically active opioid antagonist. It has primarily been used at fairly high doses to treat opioid and alcohol addiction. But at very low dosages, naltrexone has been found to have immunomodulating properties.
LDN was first used as a therapeutic agent for people with AIDS. It has been proposed for use in people with malignancies, multiple sclerosis, and autoimmune diseases. A recent publication showed a marked improvement in active Crohn’s disease for people using LDN.